US Stock Market Move | Astrazeneca PLC Sponsored ADR (AZN.US) rose more than 2% as Goldman Sachs Group, Inc. is bullish on the stock price rising to $99.

On Wednesday, Astrazeneca PLC Sponsored ADR (AZN.US) rose more than 2% to $81.99. Goldman Sachs Group, Inc. recently released a research report stating that Astrazeneca PLC Sponsored ADR had announced positive results from the Baxdrostat in the BaxHTN III clinical trial at the 2025 European Society of Cardiology (ESC) Annual Congress. Baxdrostat demonstrated strong efficacy in treating hypertension in the clinical trial and is expected to bring billions of dollars in sales opportunities to Astrazeneca PLC Sponsored ADR. Goldman Sachs Group, Inc. rated Astrazeneca PLC Sponsored ADR as "buy" with a target price of $99 in 12 months. This target price represents about a 23% upside from the stock's closing price of $80.19 on Tuesday. Data shows that Baxdrostat is a highly selective aldosterone synthase inhibitor (ASI) that targets one of the hormones leading to increased blood pressure and cardiovascular and renal risks. Currently, the drug is being tested globally with over 20,000 participants in trials, including as a monotherapy for hypertension and primary aldosteronism, and in combination with dapagliflozin for the treatment of chronic kidney disease and hypertension, as well as in the prevention of heart failure in hypertensive patients. Baxdrostat is expected to be approved in the first half of 2026 in the United States and Europe, becoming the world's first ASI antihypertensive drug on the market.